IP Library Granted Patent US 8,367,676
Granted Patent B2
US 8,367,676 · App. 12/824,567 · Granted Feb 5, 2013

2-carboxamide-7-piperazinyl-benzofuran derivatives 774

Inventors: Johan Andersson (Sodertalje, SE); Helena Gybäck (Sodertalje, SE); Anh Johansson (Sodertalje, SE); Christian Erik Linde (Sodertalje, SE); Jonas Malmström (Sodertalje, SE); Gunnar Nordvall (Sodertalje, SE); Tatjana Weigelt (Sodertalje, SE); Gitte Terp (Sodertalje, SE)
Assignee: AstraZeneca AB
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,367,676
App. No.
12/824,567
Granted
Feb 5, 2013
Kind
B2
Abstract

The present invention relates to compounds of formula (I), wherein R 1 is heteroaryl or heterocyclyl, optionally substituted; R 2 is C 1-4 alkyl, heterocyclyl, C 1-4 alkylaryl, C 1-4 alkylheteroaryl, carbocyclyl, C 1-4 alkylheterocyclyl, heterocyclyl-heteroaryl, aryl-heterocyclyl, carbocyclyl-heteroaryl, heterocyclyl-aryl, optionally substituted; R 3 is hydrogen or C 1-4 alkyl, or R 2 and R 3 may together with the nitrogen atom, form a saturated ring system containing 4, 5 or 6 ring forming atoms, and optionally substituted; R 4 is hydrogen, halogen, methyl or methoxy; to pharmaceutical composition containing said compounds and to the use of said compounds in therapy, for instance in treating cognitive disorders. The present invention further relates to new intermediates useful in the preparation thereof.

Claims (12)

1. A compound, which is N,N-dimethyl-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide, or a pharmaceutically acceptable salt thereof.

2. A compound or pharmaceutically acceptable salt thereof, wherein: the compound is N,N-dimethyl-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide; and

the compound or pharmaceutically acceptable salt is in substantially crystalline form.

3. The compound according to claim 1 , which is characterized by XRDP° 2θ (Cu Kα) values 5.48 and 9.36.

4. A pharmaceutical composition, wherein the composition comprises:

a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof according to claim 1 ; and

a pharmaceutically acceptable excipient, carrier, or diluent.

5. A pharmaceutical composition, wherein the composition comprises:

a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof according to claim 2 ; and

a pharmaceutically acceptable excipient, carrier, or diluent.

6. A pharmaceutical composition, wherein the composition comprises:

a therapeutically effective amount of the compound according to claim 3 ; and a pharmaceutically acceptable excipient, carrier, or diluent.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 5, 2019
From: ASTRAZENECA AB
To: ACTURUM LIFE SCIENCE AB
Reel/Frame 049674/0593 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 5, 2019
From: ACTURUM LIFE SCIENCE AB
To: ACTURUM REAL ESTATE AB
Reel/Frame 049674/0873 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 5, 2019
From: ACTURUM REAL ESTATE AB
To: ACTURUM LIFE AB
Reel/Frame 049675/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2010
From: ANDERSSON, JOHAN; GYBACK, HELENA; JOHANSSON, ANH; LINDE, CHRISTIAN ERIK; MALMSTROM, JONAS; NORDVALL, GUNNAR; WEIGELT, TATJANA; TERP, GITTE
To: ASTRAZENECA AB
Reel/Frame 024930/0162 →
Continuity (2)
Provisional Application 61221657 · Jun 30, 2009
Related Publication 20100331341A1 · Dec 30, 2010